Compare STVN & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STVN | LGND |
|---|---|---|
| Founded | 1949 | 1987 |
| Country | Italy | United States |
| Employees | N/A | 68 |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.7B |
| IPO Year | 2021 | N/A |
| Metric | STVN | LGND |
|---|---|---|
| Price | $13.60 | $204.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $25.67 | ★ $245.86 |
| AVG Volume (30 Days) | ★ 508.2K | 193.4K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.45% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.67 | $1.50 |
| Revenue Next Year | $9.99 | $18.28 |
| P/E Ratio | ★ $27.15 | $76.27 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.89 | $93.58 |
| 52 Week High | $28.00 | $227.92 |
| Indicator | STVN | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 37.22 | 53.79 |
| Support Level | $12.89 | $194.45 |
| Resistance Level | $16.69 | $207.72 |
| Average True Range (ATR) | 0.64 | 8.46 |
| MACD | -0.00 | -0.49 |
| Stochastic Oscillator | 30.08 | 63.62 |
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, It derives its majority revenue from Europe, Middle East and Africa.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.